A vaccine can delay the recurrence of some pancreatic and colon cancers.
Posted by giorgiobertin on January 11, 2024
A vaccine has shown potential to prevent the recurrence of KRAS-mutated pancreatic and colorectal cancers in patients who have previously undergone surgery, according to a phase I study led by researchers atUniversity of Texas MD Anderson Cancer Center. The results were published in “Nature Medicine“.
In the study, pancreatic and colorectal cancer patients considered at high risk of recurrence received a maximum of 10 doses of the vaccine ELI-002 targeting KRAS G12D and G12R mutations.
The multicenter study AMPLIFY-201 is evaluating ELI-002, a lymph node-targeted cancer vaccine designed to reduce the likelihood of these recurrences by “training” T cells to recognize KRAS mutations, allowing them to identify and eliminate KRAS mutant cells. ELI-002 is also a standard vaccine, meaning it does not have to be specially formulated for each individual. Tumors with the KRAS mutation make up approximately a quarter of all solid tumors, including 90% of pancreatic cancer patients, who most commonly have the G12D mutation.
“It’s early, but we’ve seen some promising results that this vaccine could help many of these patients avoid relapse, which could increase survival“, said the prof. Pant. “It has also shown a favorable safety profile, which is exciting.”
The results of this study have led to a Phase II study starting later this year, with a new formulation of ELI-002 targeting additional KRAS mutations.
Read the full text of the article:
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
Pant, S., Wainberg, Z.A., Weekes, C.D. et al.
Night With (2024).
ClinicalTrials.gov identifier: NCT04853017
Source: The University of Texas MD Anderson Cancer Center.
This entry was posted on gennaio 11, 2024 a 6:18 am and is filed under News-research. Tagged: Gastroenterology, immunology, oncology. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a responseor trackback from your own site.